Prooxidant properties of 5-aminosalicylic acid. Possible mechanism for its adverse side effects.
There is a growing body of experimental and clinical evidence to suggest that oral or rectal administration of 5-ASA or 5-ASA conjugates is associated with significant adverse side effects including pancreatitis, hepatitis, and renal toxicity. The objective of this study was to assess the ability of 5-ASA to interact with low-molecular-weight iron to yield oxygen-derived free radicals and to determine whether these oxidants could damage model biological compounds. We found that 5-ASA was very effective at chelating ferric iron (Fe3+), and it rapidly reduced Fe3+ to the ferrous form (Fe2+). Addition of the 5-ASA/Fe2+ chelate to solutions containing polyunsaturated fatty acids or deoxyribose resulted in lipid peroxidation and oxidative carbohydrate degradation, respectively. These results are consistent with the formation of the highly reactive (and cytotoxic) hydroxyl radical. Formation of this free radical species was confirmed by the ability of hydroxyl radical scavengers (dimethyl sulfoxide, dimethyl thiourea) to inhibit the 5-ASA/Fe-mediated oxidative reactions. Maximum hydroxyl radical formation was achieved at a 5-ASA-to-Fe3+ ratio of 1.0 (20 microM 5-ASA and 20 microM Fe3+). Increasing this ratio significantly inhibited OH. formation with a concomitant reduction in lipid peroxidation and deoxyribose degradation. Finally, we demonstrated that 5-ASA promotes the reductive release of Fe3+ from ferritin. Data obtained in this study suggest that 5-ASA may, under certain conditions, promote the formation of potentially injurious free radical species. These oxidative reactions may contribute to some of the adverse side effects known to be associated with the newer preparations of 5-ASA.
Grisham
M B
MB
Department of Physiology and Biophysics, Louisiana State University Medical Center, Shreveport 71130.
Ware
K
K
Marshall
S
S
Yamada
T
T
Sandhu
I S
IS
D000636:Aminosalicylic Acids / Q000009:adverse effects / Q000737:chemistry*; D003855:Deoxyribose; D005293:Ferritins; D015227:Lipid Peroxidation; D019804:Mesalamine; D010084:Oxidation-Reduction; D010743:Phospholipids; D013056:Spectrophotometry, Ultraviolet; D013858:Thiobarbiturates
D000636:Aminosalicylic Acids; D010743:Phospholipids; D013858:Thiobarbiturates; D019804:Mesalamine; D003855:Deoxyribose; D005293:Ferritins; C029684:thiobarbituric acid